Skip to main content
Premium Trial:

Request an Annual Quote

ActivX Biosciences Raises $20M; Elects Scripps Researcher to Company Board

NEW YORK, July 10 - ActivX Biosciences has raised $20 million in a private placement to develop the company's chemistry-based proteomics platform, the company said Tuesday. 

In addition to Oxford Bioscience Partners, who led the placement, new investors in the company include Vulcan Ventures, CIT Venture Capital, and Novo A/S. Frazier & Company and ProQuest Investments are existing investors in the company.

ActivX also said Tuesday that the company had elected Paul Schimmel, a professor of chemistry and molecular biology at the Scripps Research Institute, as chairman of its board of directors. In other management changes, the company's current president and chief scientific officer, John Kozarich, has taken over the position of CEO from Rob Hillman, who will become the company's chief operating officer. 

At Scripps, Schimmel studies the machinery for decoding genetic information, specifically tRNAs and aminoacyl tRNA synthetases. Schimmel has also helped found Alkermes, a drug-delivery company based in Cambridge, Mass., Cubist Pharmaceuticals, also in Cambridge, and Repligen, a biotechnology company in Needham, Mass.  
The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.